Articles citing this paper

From obscurity to ‘superbug’ – The rise of Clostridium difficile

Thomas V. Riley ^A

+ Author Affiliations

- Author Affiliations

^A Microbiology & Immunology, The University of Western Australia and Division of Microbiology and Infectious Diseases, PathWest Laboratory Medicine (WA), Queen Elizabeth II Medical Centre, Nedlands 6009, WA, Australia. Email: triley@cyllene.uwa.edu.au

Healthcare Infection 15(3) 59-61 https://doi.org/10.1071/HI10028
Published: 22 September 2010

6 articles found in Crossref database.

Clostridium difficile infection in Tasmanian public hospitals 2006–2010

Mitchell Brett, Ware Chris, McGregor Alistair, Brown Saffron, Wells Anne

Healthcare infection. 2011 16(3). p.101

[Crossref]

Natural products show diverse mechanisms of action againstClostridium difficile

Roshan N., Riley T.V., Knight D.R., Steer J.H., Hammer K.A.

Journal of Applied Microbiology. 2019 126(2). p.468

[Crossref]

Effects of natural products on several stages of the spore cycle ofClostridium difficile in vitro

Roshan N., Riley T.V., Hammer K.A.

Journal of Applied Microbiology. 2018 125(3). p.710

[Crossref]

Faecal Microbiota Transplantation is Effective for the Initial Treatment of Clostridium difficile Infection: A Retrospective Clinical Review

Roshan Niloufar, Clancy Annabel K., Borody Thomas J.

Infectious Diseases and Therapy. 2020 9(4). p.935

[Crossref]

Effect of natural products on the production and activity of Clostridium difficile toxins in vitro

Roshan Niloufar, Riley Thomas V., Knight Daniel R., Hammer Katherine A.

Scientific Reports. 2018 8(1).

[Crossref]

Alterations of Intestinal Microbiome by Antibiotic Therapy in Hospitalized Children

Fernandes Miriam R., Ignacio Aline, Rodrigues Viviane A.A., Groppo Franciso C., Cardoso Ary L, Avila-Campos Mario J., Nakano Viviane

Microbial Drug Resistance. 2017 23(1). p.56

[Crossref]